Galectin Therapeutics Inc. – June 15, 2016 Harold Shlevin, Ph.D. COO, Galectin Therapeutics Dear Harold, (June 20th, 2016)
The future of the Galectin Therapeutics, Inc. and the investment of its shareholders are dependent upon the successful completion of the companys ongoing clinical trials over the next few months. We are proud of the talented management team that we have assembled, and the Company has determined that it is in its best interest to assure that the team remains in place and working on the important matters before us at least through March 1, 2017.
Galectin Therapeutics Inc. – Amended and Restated Employment Agreement (December 12th, 2014)
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this Agreement) is made this 11th day of December, 2014 (the Effective Date), by and between Galectin Therapeutics Inc., a Nevada corporation (the Company), and Harold Shlevin (Executive).
Galectin Therapeutics Inc. – Employment Agreement (August 14th, 2013)
THIS EMPLOYMENT AGREEMENT (this Agreement) is made this 20th day of June, 2013, by and between Galectin Therapeutics Inc., a Nevada corporation (the Company), and Jack Callicutt, an individual residing in the State of Georgia (Executive).
Galectin Therapeutics Inc. – Amended and Restated Master Services Agreement (May 10th, 2013)
This Amended and Restated Master Services Agreement (the Agreement) is made as of the 31st day of January, 2013 (Effective Date) by and between Galectin Therapeutics (Sponsor) with offices located at 7 Wells Avenue, Suite 34, Newton, MA 02459 and CTI Clinical Trial Services, Inc. and CTI Clinical Consulting Services, Inc. (individually and collectively, CTI) with offices located at 10123 Alliance Road, Cincinnati, OH 45242.